Furthermore, experimental results have revealed that combination anti‐PD‐1 plus anti‐TIM‐3 treatment can achieve a longer overall survival than anti‐TIM‐3 monotherapy in murine gliomas.37 This evidence concerns the gene HAVCR2 and glioma.